Katherine Welles / Shutterstock.com
Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb (BMS) over patents for blood-thinner Eliquis (apixaban).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BMS, Pfizer, Eliquis, generics, Sigmapharm, FDA, patent infringement
